BioNTech SE (NASDAQ:BNTX) saw its shares rise 2.45% in pre-market trading Monday following a strong second-quarter report that doubled year-over-year revenue to €260.8 million, well above analysts’ forecast of €137.9 million.
The biotech company posted a net loss of €386.6 million, or -€1.60 per share, slightly wider than the anticipated -€1.41 per share.
The revenue surge reflects BioNTech’s ongoing strategic shift away from COVID-19 vaccines toward oncology, highlighted by a landmark collaboration with Bristol Myers Squibb (NYSE:BMY) focused on the bispecific antibody candidate BNT327. This agreement includes a $1.5 billion upfront payment expected in Q3, $2 billion in non-contingent payments through 2028, and up to $7.6 billion in milestone payments, substantially strengthening BioNTech’s financial footing.
“In the second quarter, we took significant steps to advance BioNTech into a multiproduct biotechnology company by strengthening the two pillars of our oncology strategy,” said Prof. Ugur Sahin, CEO and Co-Founder of BioNTech.
Despite the strong top-line growth, BioNTech reiterated its full-year 2025 revenue guidance of €1.7 billion to €2.2 billion, below the consensus forecast of €2.27 billion, expecting most revenue to be concentrated in the final months of the year.
The company ended Q2 with a strong cash and investment balance of €16.0 billion as of June 30, 2025. Research and development expenses fell 13% year-over-year to €509.1 million, reflecting a reprioritization of clinical trials and ongoing focus on cost discipline while advancing its oncology pipeline.
BioNTech also secured European Commission approval for its new variant-adapted COVID-19 vaccine, with deliveries slated to begin in August 2025. Additionally, the company announced plans to acquire CureVac to bolster its mRNA cancer immunotherapy capabilities, furthering its strategic transformation.
“While we continue to significantly invest into the execution of our strategy, our commitment to operational and financial discipline is starting to show tangible results,” said Ramón Zapata, Chief Financial Officer at BioNTech.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.